Complement Effector Functions and Regulation

Complement activation, regardless of which of the three initiating pathways (classical, lectin, or alternative) triggers it, converges on a single enzymatic event: cleavage of C3 by a C3 convertase into C3a and C3b. This is the branch point of the entire system. C3b covalently attaches to nearby surfaces via a reactive thioester bond, marking them as targets — this is opsonization. The small fragment C3a diffuses away as a soluble anaphylatoxin, a peptide that triggers acute inflammatory signaling. Further downstream, C3b-containing convertases cleave C5 into C5a (an even more potent anaphylatoxin) and C5b, which nucleates the membrane attack complex, a pore-forming structure that lyses the target cell directly. These three outputs are not redundant restatements of "complement destroys pathogens" — they operate through entirely different receptors and produce different physiological effects on different time scales. Opsonization operates through phagocyte-surface complement receptors (CR1/CD35, CR3/CD11b-CD18, CR4/CD11c-CD18) that recognize C3b or its inactivated fragment iC3b, converting a poorly phagocytosed microbe into an efficiently ingested one. Anaphylatoxin signaling operates through G-protein-coupled receptors (C3aR, C5aR1/CD88, C5aR2) on mast cells, neutrophils, macrophages, and endothelium, producing vasodilation, increased vascular permeability, smooth muscle contraction, and chemotactic gradients within seconds to minutes. Lysis operates through direct physical membrane disruption, independent of any receptor, and is most effective against Gram-negative bacteria and cells lacking a protective cell wall. Regulation is the necessary counterweight. Every human cell is constantly exposed to low-level "tickover" C3 activation in plasma, yet healthy erythrocytes, endothelium, and epithelium are not destroyed. This is because the human genome encodes a dedicated set of complement regulatory proteins, each targeting a specific step of the cascade: some accelerate convertase decay, some serve as cofactors for proteolytic inactivation of C3b/C4b, and some directly block MAC assembly on host membranes. The distinction between host and pathogen is not made by recognizing "self" positively so much as by the absence of protection on microbial surfaces and its presence on host surfaces — a discrimination principle worth holding onto, because it recurs throughout innate immunity.

Step 1 — Convertase formation and C3 cleavage. However triggered, all three pathways generate a C3 convertase (C4b2a for classical/lectin, C3bBb for alternative) sitting on an activating surface. This enzyme cleaves plasma C3 (present at roughly 1–1.5 mg/mL, one of the most abundant proteins in serum) into C3a (~9 kDa) and C3b (~176 kDa). The larger fragment, C3b, briefly exposes an internal thioester bond that reacts covalently with hydroxyl or amine groups on nearby surfaces, tethering it in place within milliseconds of exposure — most C3b molecules that fail to find a surface are hydrolyzed uselessly in plasma within about 60 microseconds, an inefficiency built into the design to prevent indiscriminate deposition on random tissue.

Step 2 — Opsonization and its receptors. Surface-bound C3b amplifies itself: it becomes part of new C3 convertases (via the alternative pathway amplification loop), depositing more C3b nearby, and can also combine with a convertase to form a C5 convertase. Meanwhile, Factor I (with cofactors Factor H, CD46, or CR1) progressively cleaves surface C3b into iC3b, then C3dg, then C3d. These degradation products are not "waste" — they are the actual ligands recognized by phagocyte complement receptors:

• CR1 (CD35) binds C3b and C4b; found on erythrocytes (which use it to shuttle immune complexes to the liver/spleen for clearance), phagocytes, and B cells.
• CR3 (CD11b/CD18, Mac-1) and CR4 (CD11c/CD18) bind iC3b; found on neutrophils and macrophages, and are the principal drivers of phagocytic engulfment.

Engagement of these receptors clusters phagocyte cytoskeletal machinery around the opsonized particle, triggering actin-dependent pseudopod extension that "zips" around the particle (analogous to but molecularly distinct from Fc-receptor-mediated phagocytosis), culminating in phagosome formation and fusion with lysosomes.

Step 3 — Anaphylatoxins and acute inflammation. C3a and C5a are structurally related peptides (C5a ~11 kDa) generated by proteolytic cleavage, and C5a is the more potent of the two by roughly two to three orders of magnitude in most bioassays. Both bind rhodopsin-family GPCRs:

• C3aR — expressed on mast cells, eosinophils, basophils, and some myeloid cells.
• C5aR1 (CD88) — expressed broadly on neutrophils, monocytes, mast cells, and endothelium; triggers strong chemotaxis and degranulation.
• C5aR2 (C5L2) — a poorly signaling "decoy-like" receptor that may modulate C5aR1 responses.

Ligand binding activates heterotrimeric G proteins, raising intracellular calcium and activating phospholipase C, which drives mast cell and basophil degranulation (histamine release), smooth muscle contraction, increased vascular permeability, and upregulation of endothelial adhesion molecules. C5a additionally acts as one of the most potent neutrophil chemoattractants known, establishing a gradient that recruits phagocytes to the site of complement activation. This is the molecular basis of the redness, swelling, and heat of local inflammation, and in excess (as in sepsis) systemic anaphylatoxin release contributes to shock.

Step 4 — Membrane attack complex assembly. C5 convertases (C4b2a3b or C3bBb3b) cleave C5 into C5a and C5b. Unlike C3b, C5b does not covalently attach to the membrane; instead it nucleates a non-covalent, sequential assembly: 1. C5b binds C6, forming a stable C5b-6 complex. 2. This complex binds C7, and the trimer inserts into the lipid bilayer via a conformational change that exposes hydrophobic domains. 3. C8 binds and partially inserts, beginning pore formation. 4. Multiple C9 molecules (typically 12–18) polymerize around the C5b-8 complex, forming a full transmembrane ring — the mature membrane attack complex (C5b-9). The resulting pore (an internal diameter of roughly 10 nanometers) disrupts the osmotic and ionic gradient across the membrane, causing water influx, cell swelling, and lysis. Gram-negative bacteria, whose outer membrane is directly accessible to MAC, are particularly susceptible — explaining why deficiencies in terminal complement components (C5, C6, C7, C8, C9) predispose almost exclusively to recurrent Neisseria meningitidis and Neisseria gonorrhoeae infections, while sparing susceptibility to most other pathogens (Gram-positive bacteria are generally protected by their thick peptidoglycan layer). ```

```

Regulation, mapped onto the same cascade. Every step above has a host counter-mechanism:

Host cells are protected largely because they display sialic acid and glycosaminoglycans on their surfaces, which enhance Factor H binding — Factor H preferentially recognizes sialylated surfaces, so it binds efficiently to host cell membranes but poorly to most microbial surfaces (which typically lack sialic acid decoration, though some pathogens such as Neisseria gonorrhoeae have evolved to sialylate their own surface as an immune-evasion trick, hijacking this exact discrimination mechanism). Combined with the membrane-anchored regulators CD55, CD46, and CD59 that decorate essentially all nucleated host cells and erythrocytes, this produces layered, redundant self-protection. ```

```

## The evidence

Discovery of the "alexin"/complement principle — Jules Bordet (1895–1900). Long before molecular mechanisms were known, Jules Bordet showed that fresh immune serum from an animal could lyse bacteria, but that heating the serum to 56 °C for 30 minutes abolished this lytic activity while leaving the specific antibody activity intact. He demonstrated that adding fresh, non-immune serum back to the heat-inactivated immune serum restored lysis. This proved two separable components existed: a heat-stable, specific factor (antibody) and a heat-labile, non-specific factor (which Paul Ehrlich later named "complement," because it complements antibody action). This heat-inactivation experiment remains the standard operational definition used in complement assays today — complement activity is defined precisely as the heat-labile serum component.

Identification of anaphylatoxins — direct bioassay experiments. The anaphylatoxin activity of C3a and C5a was established through classical pharmacological bioassays in the mid-20th century: purified or partially purified complement fragments were injected into guinea pigs or applied to isolated smooth muscle and mast cell preparations, reproducing the smooth-muscle contraction, vascular permeability increase, and histamine release characteristic of anaphylaxis — hence the name. Critically, these effects were shown to be independent of antibody and antigen, distinguishing them from classical (IgE-mediated) anaphylaxis and proving that complement fragments alone are sufficient to trigger mast cell degranulation and vascular changes. Later molecular work (receptor cloning in the 1990s, notably cloning of C5aR/CD88) confirmed these fragments act through dedicated GPCRs rather than nonspecific membrane effects, and receptor-knockout mice (C5aR1⁻/⁻) show blunted neutrophil recruitment and reduced vascular permeability in models of local inflammation, directly confirming the receptor's necessity in vivo.

Discovery of the membrane attack complex and electron microscopy of "complement lesions." In the 1960s–1970s, electron microscopists (including Robert Humphrey and Robert Dourmashkin, and later Jurg Tschopp's biochemical reconstitution work) observed that complement-lysed erythrocyte and bacterial membranes displayed uniform, ring-shaped, electron-dense "complement lesions" roughly 10 nm in internal diameter when examined by negative-stain electron microscopy — visually indistinguishable in size and shape from pores formed by perforin, a discovery that later illuminated a shared structural superfamily (the MACPF/perforin domain). Reconstitution experiments using purified C5b6, C7, C8, and C9 on liposomes reproduced these ring structures and lysis in a strictly sequential, order-dependent manner: omitting any single component (especially C9) reduced or abolished pore formation and lysis, directly demonstrating that the MAC is a discrete, sequentially assembled structure rather than a diffuse membrane-damaging chemical reaction. This was among the first clear demonstrations that an immune effector mechanism works through defined, stoichiometric, cooperative protein-complex assembly rather than enzymatic catalysis.

Clinical "experiments of nature" confirming regulator function. The clearest proof that CD55 and CD59 protect host cells from complement came from paroxysmal nocturnal hemoglobinuria (PNH). Patients with PNH have an acquired somatic mutation in the PIGA gene in a hematopoietic stem cell clone, which disables synthesis of the glycosylphosphatidylinositol (GPI) anchor that tethers CD55 and CD59 to the cell membrane. Their affected red blood cells, lacking these two regulators, undergo spontaneous complement-mediated intravascular hemolysis, producing the diagnostic dark morning urine (hemoglobinuria) from which the disease takes its name. Flow cytometry of PNH erythrocytes reliably shows absence of GPI-anchored CD55/CD59 (using fluorescent aerolysin, FLAER, which binds the GPI anchor directly) — a direct, quantitative confirmation, in a human natural experiment, that these two proteins are necessary and sufficient to keep host erythrocytes alive in normal serum.

## Worked examples

Example 1 — Interpreting a complement deficiency panel. A 19-year-old presents with his third episode of meningococcemia (Neisseria meningitidis bloodstream infection). His CH50 (total classical/terminal pathway hemolytic assay) is essentially zero, but his individual C3 level is normal and his IgG/IgM levels are normal. Reasoning: CH50 measures the ability of serum to lyse antibody-coated sheep erythrocytes via the full classical-to-terminal cascade; a value of zero with normal C3 tells you the defect lies downstream of C3, in the terminal components (C5, C6, C7, C8, or C9), because C3 is present and presumably functional for opsonization, but the MAC cannot form. This exact clinical pattern — recurrent Neisseria infection with normal C3 and abolished CH50 — is the classic presentation of terminal complement component deficiency, and it illustrates the earlier mechanistic point directly: Neisseria species are essentially the only common pathogens critically dependent on direct complement-mediated lysis for host control, because opsonophagocytosis (via C3b/iC3b, still intact in this patient) can compensate for most other organisms but is comparatively less effective against these particular Gram-negative diplococci in the specific niche of blood and CSF.

Example 2 — Quantifying convertase decay: why CD55 matters even at modest levels. Consider a simplified kinetic model. Suppose a C3 convertase (C3bBb) on an unprotected surface has an intrinsic half-life of 90 seconds before spontaneous dissociation, and each convertase molecule cleaves C3 at a steady rate of roughly 1 molecule of C3 per second while active. Over its lifetime, one convertase generates approximately: t½ = 90 s, mean lifetime ≈ t½ / ln(2) ≈ 130 s Total C3b generated per convertase ≈ 130 molecules. Now suppose CD55 on a host membrane accelerates decay 10-fold, reducing the effective half-life to 9 seconds (mean lifetime ≈13 s). The same convertase now generates roughly 13 molecules of C3b before disassembling — a roughly 90% reduction in local C3b deposition per convertase. Because C3b deposition is itself autocatalytic (each surface-bound C3b can nucleate a new convertase via the alternative pathway amplification loop), a 10-fold change in convertase half-life translates into a much larger, compounding reduction in total opsonization and downstream C5 convertase formation over the many amplification cycles that would otherwise occur on an unprotected surface. This simple calculation illustrates, quantitatively, why even a modest per-convertase change in decay rate produces the dramatic clinical difference between a CD55-sufficient membrane (protected) and a CD55-deficient membrane, as seen in PNH.

## Common misconceptions & traps

Complement effector biology is now directly therapeutic. Eculizumab, a monoclonal antibody that binds C5 and blocks its cleavage into C5a and C5b, prevents both anaphylatoxin-driven inflammation and MAC formation; it transformed treatment of PNH and atypical hemolytic uremic syndrome by directly targeting the pathological step identified through decades of the regulatory biology described above. Complement receptor biology underlies the design of opsonizing therapeutic antibodies in oncology (e.g., rituximab against CD20), which work partly by fixing complement on tumor cells to trigger both direct lysis and complement-receptor-mediated phagocytosis by macrophages. Genetic variants in Factor H are the strongest known genetic risk factor for age-related macular degeneration, discovered through genome-wide association studies that pointed unexpectedly back to complement regulation in retinal tissue, reshaping an entire field of ophthalmology around anti-complement therapeutics (e.g., pegcetacoplan targeting C3). In transplantation and autoimmune disease, complement regulatory proteins expressed on graft endothelium or engineered onto biomaterials help prevent hyperacute rejection and biomaterial-induced inflammation. And in vaccinology, understanding that terminal-pathway-deficient patients are selectively vulnerable to Neisseria directly justifies current public health recommendations for meningococcal vaccination in these individuals, along with eculizumab-treated patients who are placed at iatrogenic risk of the same infection and require prophylactic vaccination before starting therapy.

Ask the tutor: How does complement activation on a cell surface actually get amplified into hundreds of C3b molecules from a single triggering event, and why doesn't this positive feedback loop run away uncontrollably even on pathogen surfaces?